Failing our patients by suboptimally treating influenza infections

Clinical Infectious Diseases

Volumn 59, Issue 6, 2014, Pages 783-786

  Ison, Michael G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antibiotic; Influenza; Neuraminidase inhibitor; Oseltamivir; Zanamivir

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; SIALIDASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ANTIVIRAL THERAPY; DISEASE SEVERITY; DYSPNEA; EDITORIAL; FEVER; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNITY; INFLUENZA; MORBID OBESITY; POLYMERASE CHAIN REACTION; PREGNANCY; PRIORITY JOURNAL; AMBULATORY CARE; CLINICAL PRACTICE; DRUG UTILIZATION; INFLUENZA, HUMAN; SEASON;

AMBULATORY CARE; ANTIVIRAL AGENTS; DRUG UTILIZATION; HUMANS; INFLUENZA, HUMAN; PHYSICIAN'S PRACTICE PATTERNS; SEASONS;

EID: 84907392450     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu425     Document Type: Editorial

References (27)

1. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086-96.
2. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59:1057-62.
3. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 2012; 54:1427-36.
4. Mao L, Yang Y, Qiu Y, Yang Y. Annual economic impacts of seasonal influenza on US counties: spatial heterogeneity and patterns. Int J Health Geograp 2012; 11:16.
5. Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices - United States, 2013-2014. MMWR Recomm Rep 2013; 62:1-43.
6. Lu PJ, Santibanez TA, Williams WW, et al. Surveillance of influenza vaccination coverage-United States, 2007-08 through 2011-12 influenza seasons. MMWR Surveill Summ 2013; 62:1-28.
7. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.
8. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003-32.
9. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-73.
10. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667-72.
11. Peters PH, Moscona A, Schulman KL, Barr CE. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. Medscape J Med 2008; 10:131.
12. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 2009; 124:170-8.
13. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123-9.
14. Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis 2014; 14:109-18.
15. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156:512-24.
16. Lee N, Ison MG. Editorial commentary. "Late" treatment with neuraminidase inhibitors for severely ill patients with influenza: better late than never? Clin Infect Dis 2012; 55:1205-8.
17. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55:1198-204.
18. Doshi S, Kamimoto L, Finelli L, et al. Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009. J Infect Dis 2011; 204:1848-56.
19. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-44.
20. Skarbinski J, Jain S, Bramley A, et al. Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States - September-October 2009. Clin Infect Dis 2011; 52(suppl 1):S50-9.
21. Havers F, Thaker S, Clippard JR, et al. Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season. Clin Infect Dis 2014; 59:774-82.
22. Madjid M, Curkendall S, Blumentals WA. The influence of oseltamivir treatment on the risk of stroke after influenza infection. Cardiology 2009; 113:98-107.
23. Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ. Health outcomes among patients receiving oseltamivir. Pharmacoepidemiol Drug Saf 2004; 13:227-37.
24. Gums JG, Pelletier EM, Blumentals WA. Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother 2008; 9:151-61.
25. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: CDC, 2013.
26. Centers for Disease Control and Prevention. Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) virus - United States, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:826-9.
27. Van Kerkhove MD, Vandemaele KA, Shinde V, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011; 8:e1001053.